In This Article:
On September 12, 2024, Jason Haas, Chief Financial Officer of Syros Pharmaceuticals Inc (NASDAQ:SYRS), purchased 100,000 shares of the company, as reported in a recent SEC Filing. This transaction increased the insider's total ownership to 124,552 shares.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) is a biopharmaceutical company focused on the development of treatments for cancer and diseases caused by gene expression dysregulation. The insider's purchase is one of three insider buys over the past year, compared to four insider sells during the same period.
On the day of the transaction, shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) were priced at $1.61, valuing the company with a market cap of $42.094 million. According to the GF Value, the intrinsic value estimate for the stock is $0.55, indicating a price-to-GF-Value ratio of 2.93. This suggests that the stock is significantly overvalued based on its GF Value.
The GF Value is calculated considering historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
Over the past year, Jason Haas has increased his holdings in Syros Pharmaceuticals Inc (NASDAQ:SYRS) by purchasing 100,000 shares, with no recorded sales of shares by the insider.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.